Summary Novo Nordisk has transferred a Parkinson’s disease cell therapy program to Cellular Intelligence, reflecting continued asset recycling and lifecycle extension within the advanced cell therapy ecosystem. What Happened Cellular Intelligence, an AI-focused biotechnology company, acquired rights to a discontinued…
Summary Fractyl Health has received authorization in the Netherlands to initiate the first-in-human clinical trial of RJVA-001, an AAV-based gene therapy for type 2 diabetes, marking the first clinical-stage gene therapy program targeting the disease. What Happened The Dutch regulatory…
Company Takeda Pharmaceutical (Osaka / Cambridge, MA) Event Type Phase 2/3 pivotal trial topline results — primary endpoint met Modality Plasma-derived immunoglobulin SC with recombinant human hyaluronidase Target IgG replacement / immune reconstitution Indication Primary Immunodeficiency Disease (PID) — adults…
Summary Intellia Therapeutics reported that its in vivo CRISPR gene-editing therapy, lonvoguran ziclumeran (lonvo-z), met its Phase 3 primary endpoint in hereditary angioedema, reducing swelling attacks by 87% versus placebo and advancing toward FDA submission. What Happened Intellia announced positive…
Summary CorMedix reported positive Phase 3 results from the ReSPECT trial for rezafungin (REZZAYO), demonstrating non-inferiority to standard antimicrobial regimens for prevention of invasive fungal disease (IFD) in allogeneic hematopoietic stem cell transplant (allo-HSCT) patients. What Happened The Phase 3…
Summary Compass Therapeutics reported that its DLL4xVEGF-A bispecific antibody, tovecimig, failed to meet the overall survival (OS) endpoint in a Phase 2/3 trial in biliary tract cancer, despite showing a statistically significant progression-free survival (PFS) benefit. What Happened In the…
Summary Pfizer has discontinued a Phase 1 immunostimulatory drug-conjugate program in oncology, highlighting challenges in developing next-generation targeted delivery modalities. What Happened Pfizer ended development of an early-stage immunostimulatory drug-conjugate candidate that had been in Phase 1 testing. The program…
Summary Allogene Therapeutics announced it will present an interim futility analysis from its pivotal Phase 2 ALPHA3 trial of an allogeneic CAR-T therapy in first-line consolidation for large B-cell lymphoma (LBCL), with data expected on April 13, 2026. What Happened…
Summary Gilead Sciences has agreed to acquire German biotech Tubulis in a deal worth up to $5 billion, significantly expanding its antibody-drug conjugate (ADC) platform capabilities. The transaction underscores the strategic importance of ADC technologies in next-generation oncology pipelines. What…
Summary Astellas has declined to exercise its option on AviadoBio’s AAV-based gene therapy program targeting frontotemporal dementia (FTD), but the program will continue through nonprofit funding support. The development highlights an alternative pathway for sustaining high-risk, rare-disease programs despite pharmaceutical…
